** Shares of AIM Vaccine Co Ltd 6660.HK jump as much as 13.2% to HK$6.35; on course for biggest one-day gain since October 17, 2024
** Stock on track for the second session of gain
** AIM says U.S. Food and Drug Administration (FDA) has approved its application for clinical trial of mRNA respiratory syncytial virus vaccines
** The Chinese mRNA vaccine products developer says it is U.S. FDA's first approval for the company's products, marking a "significant progress" for its global strategy
** Hang Seng Commerce & Industry Index .HSNC and Hang Seng Index .HSI both add 0.1%, healthcare index .HSCIH gains 0.2%
** Stock up 1.5% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。